Exhibits phosphatidylcholine-sterol O-acyltransferase activity and phospholipase A2 activity. Involved in several processes, including cholesterol metabolic process; response to copper ion; and response to glucocorticoid. Predicted to localize to high-density lipoprotein particle. Used to study end stage renal disease; familial hyperlipidemia; and myocardial infarction. Human ortholog(s) of this gene implicated in Norum disease and arteriosclerosis. Orthologous to human LCAT (lecithin-cholesterol acyltransferase); PARTICIPATES IN reverse cholesterol transport pathway; glycerophospholipid metabolic pathway; INTERACTS WITH (+)-alpha-tocopherol; (+)-schisandrin B; (-)-epigallocatechin 3-gallate.
[Quercetin co-treated with alpha-Tocopherol] inhibits the reaction [Cadmium results in decreased activity of LCAT protein], [Quercetin co-treated with alpha-Tocopherol] inhibits the reaction [Isoproterenol results in decreased activity of LCAT protein]
[tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein], Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]
[Clofibrate co-treated with Acetaminophen] affects the expression of LCAT mRNA, PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of LCAT mRNA]
[[gluconic acid results in increased abundance of Magnesium] co-treated with [Sodium Selenite results in increased abundance of Selenium]] inhibits the reaction [Dietary Fats results in decreased expression of LCAT mRNA]
Dichlorvos inhibits the reaction [[LCAT protein results in increased metabolism of Lecithins] which results in increased chemical synthesis of Cholesterol Esters]
[[gluconic acid results in increased abundance of Magnesium] co-treated with [Sodium Selenite results in increased abundance of Selenium]] inhibits the reaction [Dietary Fats results in decreased expression of LCAT mRNA]
[[gluconic acid results in increased abundance of Magnesium] co-treated with [Sodium Selenite results in increased abundance of Selenium]] inhibits the reaction [Dietary Fats results in decreased expression of LCAT mRNA]
Fenitrothion inhibits the reaction [[LCAT protein results in increased metabolism of Lecithins] which results in increased chemical synthesis of Cholesterol Esters]
[[gluconic acid results in increased abundance of Magnesium] co-treated with [Sodium Selenite results in increased abundance of Selenium]] inhibits the reaction [Dietary Fats results in decreased expression of LCAT mRNA]
[Clofibrate co-treated with Acetaminophen] affects the expression of LCAT mRNA, PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of LCAT mRNA]
Methyl Parathion inhibits the reaction [[LCAT protein results in increased metabolism of Lecithins] which results in increased chemical synthesis of Cholesterol Esters]
[Quercetin co-treated with alpha-Tocopherol] inhibits the reaction [Cadmium results in decreased activity of LCAT protein], [Quercetin co-treated with alpha-Tocopherol] inhibits the reaction [Isoproterenol results in decreased activity of LCAT protein]
[[gluconic acid results in increased abundance of Magnesium] co-treated with [Sodium Selenite results in increased abundance of Selenium]] inhibits the reaction [Dietary Fats results in decreased expression of LCAT mRNA]
[tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein], tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]
[Quercetin co-treated with alpha-Tocopherol] inhibits the reaction [Cadmium results in decreased activity of LCAT protein], [Quercetin co-treated with alpha-Tocopherol] inhibits the reaction [Isoproterenol results in decreased activity of LCAT protein]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
